Arvinas (ARVN) Net Income towards Common Stockholders Growth (1y) (2018 - 2026)
Powered by 
Analysis
Arvinas (ARVN) Net Income towards Common Stockholders Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -12.04% |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 95.87% |
| 10 | Arvinas | 611.71 Mn | 43.81 Mn | - | 376.80% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 376.80% |
| Mar 31, 2026 | -169.48% |
| Dec 31, 2025 | -49.45% |
| Sep 30, 2025 | 28.66% |
| Jun 30, 2025 | -73.86% |
| Mar 31, 2025 | 219.45% |
| Dec 31, 2024 | 70.87% |
| Sep 30, 2024 | 23.00% |
| Jun 30, 2024 | 46.09% |
| Mar 31, 2024 | 14.11% |
| Dec 31, 2023 | -93.26% |
| Sep 30, 2023 | -0.95% |
| Jun 30, 2023 | 3.26% |
| Mar 31, 2023 | -32.24% |
| Dec 31, 2022 | -73.75% |
| Sep 30, 2022 | -35.26% |
| Jun 30, 2022 | -34.19% |
| Mar 31, 2022 | -49.02% |
| Dec 31, 2021 | -18.90% |
| Sep 30, 2021 | -51.14% |